Unicycive Therapeutics (UNCY) Q2 2025 earnings summary

Executive summary

• Focused on developing therapies for kidney disease, with two main programs: Oxylanthanum Carbonate (OLC) for hyperphosphatemia and UNI-494 for acute kidney injury.

• Requested a Type A meeting with the FDA to address the Complete Response Letter for OLC, aiming for regulatory approval.

• Published pivotal study data showing OLC was well tolerated and enabled serum phosphate control in over 90% of dialysis patients with a low pill burden.

• Ended Q2 2025 with $22.3 million in cash, projecting operational runway into the second half of 2026.

• Net loss for the six months ended June 30, 2025 was $5.9 million, a 47% improvement year-over-year.

Financial highlights

• Revenue not yet generated; operations funded by equity and preferred stock offerings.

• Research and development expenses decreased 66% year-over-year to $3.9 million for the six months ended June 30, 2025; Q2 2025 R&D expenses were $1.8 million.

• General and administrative expenses increased 124% year-over-year to $11.0 million for the six months ended June 30, 2025; Q2 2025 G&A expenses were $5.2 million.

• Net cash used in operating activities was $17.3 million for the six months ended June 30, 2025.

• Cash and cash equivalents at June 30, 2025 were $22.3 million.

Outlook and guidance

• Expects continued operating losses and negative cash flows as R&D and commercialization efforts expand.

• Sufficient cash resources to fund operations into the second half of 2026.

• Management believes current resources are sufficient for at least one year, but additional capital will be needed for future development and commercialization.

• Plans to provide an investor update in Q3 2025 after receiving FDA feedback.